Cited by 117Pulmonary Hypertension Research and TreatmentsVascular Anomalies and TreatmentsSystemic Sclerosis and Related Diseases

The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.

Pathways in pulmonary arterial hypertension: the future is here

Open access

Sitbon, Olivier, Morrell, NicholasW.·2012·European Respiratory Review

DOI 10.1183/09059180.00004812PMC PMC9487224

Open this paper in CoChat — free account

Abstract

It is well established that the endothelin, nitric oxide and prostacyclin pathways play an important role in the development of pulmonary arterial hypertension (PAH). Indeed, the therapeutic options currently available for the management of PAH all act on one of these mechanistic pathways. However, this is an exciting time for both clinicians and scientists, as increased understanding of the mechanisms involved in the pathogenesis and progression of PAH has resulted in the development of a number of novel therapeutic options. This article highlights how the introduction of new compounds such as macitentan, riociguat and selexipag, which act on the endothelin, nitric oxide and prostacyclin pathways, respectively, have the potential to further improve the prognosis for patients with PAH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1183/09059180.00004812

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E., & Chaudhuri, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9265 · Cited by 5,074
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R. D., Shennib, H., Kimura, S., Masaki, Τ., Duguid, W. P., & Stewart, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282402 · Cited by 1,838
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,724
Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations
Arnold, W. P., Mittal, C. K., Katsuki, S., & Murad, F. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.8.3203 · Cited by 1,459
An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension
Christman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. Μ., & Loyd, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270202 · Cited by 1,182
Tadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,096
Reversal of experimental pulmonary hypertension by PDGF inhibition
SCHERMULY, R. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24838 · Cited by 1,080
Prostacyclin Synthase Expression Is Decreased in Lungs from Patients with Severe Pulmonary Hypertension
Tuder, R. M., Cool, C. D., Geraci, M. W., Wang, J., Abman, S. H., Wright, L. A., Badesch, D. B., & Voelkel, N. F. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.6.9804054 · Cited by 804
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 667

Show all 59 references

Research works printed but not linked: 1

Sidharta, 2010, Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects, Br J Clin Pharmacol, 70, 730

Sorted by citations

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
McLaughlin, V. V., Channick, R. N., Ghofrani, H. A., Lemarié, J.-C., Naeije, R., Packer, M., Souza, R., Tapson, V. F., Tolson, J., Al‐Hiti, H., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.02044-2014 · Cited by 227
Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health
Koch, C. D., Gladwin, M. T., Freeman, B. A., Lundberg, J. O., Weitzberg, E., & Morris, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.015 · Cited by 186
Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension
Sheikh, A. Q., Misra, A., Rosas, I. O., Adams, R. H., & Greif, D. M. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa9712 · Cited by 174
The role of endothelin-1 in pulmonary arterial hypertension
Chester, A. H., & Yacoub, M. H. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.29 · Cited by 149
Pyrazine derivatives: a patent review (June 2012 – present)
Doležal, M., & Zítko, J. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.982533 · Cited by 112
Functional polymorphism of lncRNA MALAT1 contributes to pulmonary arterial hypertension susceptibility in Chinese people
Zhuo, Y., Zeng, Q., Zhang, P., Li, G., Xie, Q., & Cheng, Y. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0056 · Cited by 98
Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
Lang, I. M., & Gaine, S. (2015) · European Respiratory Review · doi:10.1183/16000617.0067-2015 · Cited by 101
Current and emerging therapeutic approaches to pulmonary hypertension
Bisserier, M., Pradhan, N. M., & Hadri, L. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.02.597 · Cited by 86
Locally and traditionally used Ligusticum species – A review of their phytochemistry, pharmacology and pharmacokinetics
Donkor, P. O., Chen, Y., Ding, L., & Qiu, F. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.10.012 · Cited by 83
Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension
Dingemanse, J., Sidharta, P. N., Maddrey, W. C., Rubin, L. J., & Mickail, H. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.859674 · Cited by 75
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
Kaufmann, P., Okubo, K., Bruderer, S., Mant, T., Yamada, T., Dingemanse, J., & Mukai, H. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0117-4 · Cited by 69
Management of Pulmonary Arterial Hypertension
Mayeux, J. D., Pan, I. Z., Dechand, J., Jacobs, J. A., Jones, T. L., McKellar, S. H., Beck, E. M., Hatton, N. D., & Ryan, J. J. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00663-3 · Cited by 68
Pulmonary arterial hypertension associated with congenital heart disease: Recent advances and future directions
Gatzoulis, M. Α., Beghetti, M., Landzberg, M. J., & Galiè, N. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.024 · Cited by 68
Endothelial Krüppel-Like Factor 4 Modulates Pulmonary Arterial Hypertension
Shatat, M. A., Tian, H., Zhang, R., Tandon, G., Hale, A. T., Fritz, J. S., Zhou, G., Martínez‐González, J., Rodrı́guez, C., Champion, H. C., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0135oc · Cited by 64
Pd/PTABS: Catalyst for Room Temperature Amination of Heteroarenes
Bandaru, S. S. M., Bhilare, S. A., Chrysochos, N., Gayakhe, V., Trentin, I., Schulzke, C., & Kapdi, A. R. (2018) · Organic Letters · doi:10.1021/acs.orglett.7b03854 · Cited by 64
Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects
Bruderer, S., Hurst, N., Kaufmann, P., & Dingemanse, J. (2014) · Pharmacology · doi:10.1159/000367630 · Cited by 58
The role of combination therapy in managing pulmonary arterial hypertension
Ghofrani, H. A., & Humbert, M. J. C. (2014) · European Respiratory Review · doi:10.1183/09059180.00007314 · Cited by 54
Single-cell transcriptomic profile of human pulmonary artery endothelial cells in health and pulmonary arterial hypertension
Asosingh, K., COMHAIR, S. A. A., Mavrakis, L. A., Xu, W., Horton, D., Taylor, I., Tkachenko, S., Hu, B., & ERZURUM, S. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-94163-y · Cited by 54
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Marra, A. M., Egenlauf, B., Ehlken, N., Fischer, C., Eichstaedt, C. A., Nagel, C., Bossone, E., Cittadini, A., Halank, M., Gall, H. J., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.105 · Cited by 52
Vascular Endothelial Growth Factor Receptor 3 Regulates Endothelial Function Through β-Arrestin 1
Ma, Z., Yu, Y.-R. A., Badea, C. T., Kovacs, J. J., Xiong, X., COMHAIR, S. A. A., Piantadosi, C. A., & Rajagopal, S. (2019) · Circulation · doi:10.1161/circulationaha.118.034961 · Cited by 52
Macitentan: First Global Approval
Patel, T., & McKeage, K. (2013) · Drugs · doi:10.1007/s40265-013-0156-6 · Cited by 49
Nitric oxide and pulmonary arterial hypertension
Chester, A. H., Yacoub, M. H., & Moncada, S. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.14 · Cited by 51
New horizons in pulmonary arterial hypertension therapies
Galiè, N., & Ghofrani, H. A. (2013) · European Respiratory Review · doi:10.1183/09059180.00006613 · Cited by 44
Purinergic dysregulation in pulmonary hypertension
Visovatti, S., Hyman, M. C., Goonewardena, S. N., Anyanwu, A. C., Kanthi, Y. M., Robichaud, P., Wang, J., Petrovic‐Djergovic, D., Rattan, R., Burant, C., et al. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00572.2015 · Cited by 44
Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation
Leifer, F., Konicek, D., Chen, K., Plaunt, A. J., Salvail, D., Laurent, C. E., Corboz, M. R., Li, Z., Chapman, R., Perkins, W. R., et al. (2018) · Drug Research · doi:10.1055/s-0044-100374 · Cited by 42
Gender-related differences in pulmonary arterial hypertension targeted drugs administration
Marra, A. M., Benjamin, N., Eichstaedt, C. A., Salzano, A., Arcopinto, M., Gargani, L., D’Alto, M., Argiento, P., Falsetti, L., Giosia, P. D., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.018 · Cited by 40
Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension
Freund‐Michel, V., Santos, M. C. D., Guignabert, C., Montani, D., Phan, C., Coste, F., Tu, L., Dubois, M., Girerd, B., Courtois, A., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201410-1851oc · Cited by 38
A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension
Bedan, M., Grimm, D. G., Wehland, M., Simonsen, U., Infanger, M., & Krüger, M. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13033 · Cited by 36
Selexipag for the treatment of pulmonary arterial hypertension
Sharma, K. H. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1121103 · Cited by 36
Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension
Narechania, S., Torbic, H., & Tonelli, A. R. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419877409 · Cited by 35
HFIP Promoted Low-Temperature SNAr of Chloroheteroarenes Using Thiols and Amines
Bhujabal, Y. B., Vadagaonkar, K. S., Gholap, A., Sanghvi, Y. S., Dandela, R., & Kapdi, A. R. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02371 · Cited by 33
The Search for Disease-Modifying Therapies in Pulmonary Hypertension
Woodcock, C.-. C., & Chan, S. Y. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419829172 · Cited by 31
Macitentan: An important addition to the treatment of pulmonary arterial hypertension
Khadka, A., Brashier, D. B. S., Anantharamu, T., & Sharma, A. K. (2015) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.149151 · Cited by 29
Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
Belge, C., & Delcroix, M. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618823440 · Cited by 28
Long noncoding RNAs: emerging roles in pulmonary hypertension
Jin, Q., Zhao, Z., Zhao, Q., Yu, X. L., Yan, L., Zhang, Y., Luo, Q., & Liu, Z. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09866-2 · Cited by 27
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects
Bruderer, S., Okubo, K., Mukai, H., Mant, T., & Dingemanse, J. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.014 · Cited by 25
Functional Prostacyclin Synthase Promoter Polymorphisms. Impact in Pulmonary Arterial Hypertension
Stearman, R. S., Cornelius, A. R., Xiao, L., Conklin, D. S., Rosario, M. J. D., Taylor, A. L., Elos, M. T., Fettig, L. M., Wong, R., Hara, N., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1697oc · Cited by 25
Treatment of pediatric pulmonary arterial hypertension: A focus on the NO‐sGC‐cGMP pathway
Beghetti, M., Gorenflo, M., Ivy, D. D., Moledina, S., & Bonnet, D. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24442 · Cited by 25
β-Arrestin–Mediated Angiotensin II Type 1 Receptor Activation Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension
Ma, Z., Viswanathan, G., Sellig, M., Jassal, C., Choi, I., Garikipati, A., Xiong, X., Nazo, N., & Rajagopal, S. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.09.006 · Cited by 25
An overview of the biology of a long-acting inhaled treprostinil prodrug
Chapman, R. W., Corboz, M. R., Malinin, V., Plaunt, A. J., Konicek, D. M., Li, Z., & Perkins, W. R. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102002 · Cited by 23
Pulmonary hypertension in β thalassaemia
Anthi, A., Orfanos, S. E., & Armaganidis, A. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70078-x · Cited by 23
Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension
Fazal, S., Bisserier, M., & Hadri, L. (2021) · Cells · doi:10.3390/cells10030638 · Cited by 27
Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling
Gomes, M. T., Bai, Y., Potje, S. R., Zhang, L., Lockett, A. D., & Machado, R. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052410 · Cited by 22
An Update on Medical Therapy for Pulmonary Arterial Hypertension
Wu, Y., O’Callaghan, D. S., & Humbert, M. J. C. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0394-8 · Cited by 20
Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Mielniczuk, L. M., Swiston, J. R., & Mehta, S. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.014 · Cited by 16
Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
Davila, C. D., & Monaco, T. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s88612 · Cited by 16
Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?
Howard, L., Ferrari, P., & Mehta, S. (2014) · European Respiratory Review · doi:10.1183/09059180.00007514 · Cited by 16
Medical therapies for pulmonary arterial hypertension
Pulido, T., Zayas, N., Mendieta, M. A.-D., Plascencia, K., & Escobar, J. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9527-x · Cited by 16
Pulmonary Arterial Hypertension
Patel, B. B., Feng, Y., & Cheng-Lai, A. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000042 · Cited by 15
Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
Kuc, R. E., Carlebur, M., Maguire, J. J., Yang, P. B., Long, L., Toshner, M. R., Morrell, N. W., & Davenport, A. P. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.02.020 · Cited by 15
Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats
Koga, M., Mizuno, Y., Watanabe, I., Kawakami, H., & Goto, T. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00861.2013 · Cited by 14
Oxidative Coupling: A Tranquil Approach for Determination of Selexipag by Visible Spectrophotometry
Gorumutchu, G. P., & Ratnakaram, V. N. (2018) · Oriental Journal Of Chemistry · doi:10.13005/ojc/340656 · Cited by 14
Sex- and Gender-Related Aspects in Pulmonary Hypertension
D'Agostino, A. G., Guindani, P., Scaglione, G., Vincenzo, A. D., Tamascelli, S., Spaggiari, R., Salzano, A., D’Amuri, A., Marra, A. M., Pilote, L., et al. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.09.002 · Cited by 14
Pulmonary arterial hypertension: bridging the present to the future
Humbert, M. J. C., Souza, R., Galiè, N., McLaughlin, V. V., Simonneau, G., & Rubin, L. J. (2012) · European Respiratory Review · doi:10.1183/09059180.00005312 · Cited by 13
Sex and Gender Differences in Cardiovascular Disease
Groban, L., Lindsey, S. H., Wang, H., & Alencar, A. K. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802388-4.00005-7 · Cited by 13
Pharmacokinetic–Pharmacodynamic Relationships of Macitentan, a New Endothelin Receptor Antagonist, After Multiple Dosing in Healthy Korean Subjects
Ahn, L. Y., Kim, S. E., Yi, S., Dingemanse, J., Lim, K. S., Jang, I., & Yu, K. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0081-4 · Cited by 12
The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies
Jasińska-Stroschein, M., & Orszulak–Michalak, D. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.04.001 · Cited by 11
Diligustilide releases H2S and stabilizes S-nitrosothiols in ethanol-induced lesions on rat gastric mucosa
Velázquez-Moyado, J. A., Balderas-López, J. L., Pineda‐Peña, E. A., Sánchez-Ortíz, B. L., Carvalho, J. C. T., & Navarrete, A. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0392-6 · Cited by 11
A Review of Pulmonary Arterial Hypertension Treatment in Extracorporeal Membrane Oxygenation: A Case Series of Adult Patients
Torbic, H., Hohlfelder, B., Krishnan, S., & Tonelli, A. R. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211069005 · Cited by 11
Macitentan: A Review of Its Use in Patients with Pulmonary Arterial Hypertension
Dhillon, S. (2014) · Drugs · doi:10.1007/s40265-014-0266-9 · Cited by 11
Advanced Therapy in Eisenmenger Syndrome
Hjortshøj, C. S., Jensen, A. S., & Søndergaard, L. (2016) · Cardiology in Review · doi:10.1097/crd.0000000000000107 · Cited by 11
Development of an efficient stability‐indicating LC–MS/MS method for the analysis of selexipag and characterization of its degradation products
Babu, N. L. A. A., Koganti, K., Palakeeti, B., Srinivas, K. S. V., & Rao, K. P. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5178 · Cited by 10
Apela gene therapy alleviates pulmonary hypertension in rats
Hu, Y., Jin, L., Pan, Y., Zou, J., & Wang, Z. (2022) · The FASEB Journal · doi:10.1096/fj.202200266r · Cited by 10
Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
Veeroju, S., Kojonazarov, B. K., Weiß, A., Ghofrani, H. A., Weißmann, N., Grimminger, F., Seeger, W., Novoyatleva, T., & SCHERMULY, R. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031502 · Cited by 9
Involvement of Ca2+-activated K+ channel 3.1 in hypoxia-induced pulmonary arterial hypertension and therapeutic effects of TRAM-34 in rats
Guo, S., Shen, Y., He, G., Wang, T., Xu, D., & Wen, F. (2017) · Bioscience Reports · doi:10.1042/bsr20170763 · Cited by 8
CONTEMPORARY STRATEGY OF PULMONARY HYPERTENSION MANAGEMENT IN PEDIATRICS
Miklashevich, I. M., Shkolnikova, M. A., Gorbachevsky, S. V., Shmalts, A. A., Groznova, O. S., Sadykova, D. I., Yakovleva, L. V., Degtyarev, D. N., Александрович, Б. А., Ovsyannikov, D. Y., et al. (2018) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2018-2-101-124 · Cited by 8
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
Gorini, F., Santoro, M. C., Pierini, A., Mezzasalma, L., Baldacci, S., Bargagli, E., Boncristiano, A., Brunetto, M. R., Cameli, P., Cappelli, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869842 · Cited by 8
Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies
Ghosh, R. K., Ball, S., Das, A., Bandyopadhyay, D., Mondal, S., Saha, D., & Gupta, A. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.834 · Cited by 8
Characterization of degradation products of macitentan under various stress conditions using liquid chromatography/mass spectrometry
Yerra, N. V., Pallerla, P., Pandeti, S., Tabet, J., & Thota, J. R. (2018) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8138 · Cited by 8
Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
Mohammadi, A., Matos, W. F., Intriago, C., Thakkar, K., Jahan, N., Shah, H., Nishu, R. I., & Marzban, S. (2021) · Cureus · doi:10.7759/cureus.18191 · Cited by 7
Reduced Apela/APJ system expression in patients with pulmonary artery hypertension secondary to chronic obstructive pulmonary disease
Hu, Y., Zong, Y., Jin, L., Zou, J., & Wang, Z. (2023) · Heart & Lung · doi:10.1016/j.hrtlng.2023.01.008 · Cited by 7
The Occurrence Of Winged Females In The Ant Genus Leptogenys Roger, With Descriptions Of New Species.
Wheeler, W. M. (1923) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.25193 · Cited by 7
VEGFPromoter Polymorphism Confers an Increased Risk of Pulmonary Arterial Hypertension in a Chinese Population
Zhuo, Y., Zeng, Q., Zhāng, P., Li, G., Xie, Q., & Cheng, Y. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.2.305 · Cited by 7
Unraveling the pathogenesis of viral-induced pulmonary arterial hypertension: Possible new therapeutic avenues with mesenchymal stromal cells and their derivatives.
Castillo‐Galán, S., Parra, V., & Cuenca, J. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167519 · Cited by 6
Macitentan for the treatment of pulmonary arterial hypertension
DuBrock, H. M., & Channick, R. N. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2014.937708 · Cited by 6
Update on Medical Management of Pulmonary Arterial Hypertension
Sherman, A. E., Saggar, R., & Channick, R. N. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.002 · Cited by 6
Management of Pulmonary Hypertension in the Pediatric Patient
Epstein, R., & Krishnan, U. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.010 · Cited by 5
QSAR Study of Some Natural and Synthetic Platelet Aggregation Inhibitors and their Pharmacological Profile
Dembitsky, V. M., Gloriozova, T. A., Poroikov, V., & Koola, M. M. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.120503 · Cited by 5
Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
Tong, Y., Jiao, Q., Liu, Y., Lv, J., Wang, R., & Zhu, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01032 · Cited by 5
Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review
Bongiovanni, G., Tonutti, A., Stainer, A., Nigro, M., Kellogg, D. L., Nambiar, A. M., Gramegna, A., Mantero, M., Voza, A., Blasi, F., et al. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-002161 · Cited by 4
A Novel Synthesis of Macitentan, an Endothelin Receptor Antagonist
Nami, M., Sovari, S. N., Haghighatnia, Y., Dabiri, M., & Salehi, P. (2017) · Organic Preparations and Procedures International · doi:10.1080/00304948.2017.1320921 · Cited by 4
Pathogenesis of Pulmonary Arterial Hypertension
Tuder, R. M., Ponticos, M., & Holmes, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_26 · Cited by 4
A paradigm shift in pulmonary arterial hypertension management
Rubin, L. J., Galiè, N., Simonneau, G., & McLaughlin, V. V. (2013) · European Respiratory Review · doi:10.1183/09059180.00006913 · Cited by 3
Antagonistas de los receptores de la endotelina para la hipertensión arterial pulmonar
Bevacqua, R. J., Bortman, G., & Perrone, S. V. (2013) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 3
Idiopathic pulmonary arterial hypertension: current approach to diagnosis and pharmacological treatment
Tsareva, N. A. (2017) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-2-216-231 · Cited by 3
Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments
Norman, P. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.924851 · Cited by 2
Vascular Dysfunction in Pneumocystis-Associated Pulmonary Hypertension Is Related to Endothelin Response and Adrenomedullin Concentration
Siemsen, D. W., Dobrinen, E., Han, S. J., Chiocchi, K., Meissner, N. N., & Swain, S. D. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.10.008 · Cited by 2
Promising signalling pathways for the treatment of pulmonary arterial hypertension
Budhram, B., Bonnet, S., & Weatherald, J. C. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001278 · Cited by 1
Avances futuros en la hipertensión arterial pulmonar
Bevacqua, R. J., & Perrone, S. V. (2013) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 1
A Comprehensive Drug Review on Macitentan: A Preeminent Inclusion to Pulmonary Arterial Hypertension Therapy
Bahl, D., Jaiswal, R. K., Ahsan, M., Bano, F., An, M., Khan, D., Husain, A., Ahmad, A. M., Al-Abbasi, F. A., & Khan, S. A. (2015) · Cited by 1
Palliative Care in Pulmonary Arterial Hypertension
Christiansen, D. L., Weatherald, J. C., & Orlikow, E. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_14 · Cited by 1
Bosentan Is Associated with a Reduction in Right Ventricular Systolic Pressure N-Terminal Pro-Hormone B-Type Natriuretic Peptide Levels in Young Patients with Pulmonary Hypertension
Landry, L. M., Burks, A. C., Osakwe, O., Knudson, J. D., & Jenks, C. L. (2023) · Open Journal of Pediatrics · doi:10.4236/ojped.2023.131004 · Cited by 1
Etiology, diagnosis and treatments of pulmonary hypertension
Chen, Y. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3013013 · Cited by 1
Differential inhibition of sildenafil and macitentan on saxagliptin metabolism
Dai, G., Tan, W., Shen, Y., Lin, D., Xu, R.-A., Lin, Q., & Wei, Z. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116934 · Cited by 1
Copper catalysis for pyrazines and quinoxalines
Mitra, B., & Ghosh, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821263-9.00006-0 · Cited by 1
Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group
Krishnan, U., & Rosenzweig, E. B. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4999-6_205-2
Estrogen metabolism in pulmonary arterial hypertension
Johansen, Z., & Katrine, A. (2014) · Enlighten: Theses (The University of Glasgow)
Complex Raynaud’s phenomenon: evolving concepts of management
Meier, F. M., Frerix, M., & Müller‐Ladner, U. (2013) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.13.65
Macitentan: a guide to its use in the treatment of pulmonary arterial hypertension in adults of WHO functional class II or III in the EU
Lyseng-Williamson, K. A., Yang, L. P. H., & Dhillon, S. (2014) · Drugs & Therapy Perspectives · doi:10.1007/s40267-014-0180-y
Riociguat, a guanylate cyclase stimulator for the treatment of pulmonary hypertension
Priyadharsini, R. P., & Padmapriya, R. (2014) · Journal of Young Pharmacists · doi:10.5530/jyp.2014.2.4

Authors: Sitbon, O., & Morrell, N.
Affiliations: Université Paris-Sud (FR)
ORCID: Sitbon, Olivier
Venue: European Respiratory Review
Publisher: European Respiratory Society (ERS)
Published: 2012-11-30
Volume: 21
Issue: 126
Pages: 321-327
ISSN: 0905-9180 (ISSN-L)
1600-0617
DOI: 10.1183/09059180.00004812
PMC: PMC9487224
OpenAlex: W2163323710
Cited by: 117
References: 59
Citations by year: 2026: 3 · 2024: 6 · 2023: 2 · 2022: 7 · 2021: 14 · 2020: 3 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 12 · 2015: 10 · 2014: 21 · 2013: 11 · 2012: 1
FWCI: 2.32
Type: journal article
Language: en
Open access: diamond
doi.org
Locations: European Respiratory Review (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Actelion Pharmaceuticals
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords: pulmonary arterial hypertension, endothelin pathway, nitric oxide pathway, prostacyclin pathway, macitentan, riociguat, selexipag, PAH therapy, endothelin receptor antagonists, soluble guanylate cyclase stimulator, prostacyclin analogues
MeSH terms: Imatinib Mesylate, Acetamides, Animals, Antihypertensive Agents, Benzamides, Clinical Trials as Topic, Guanylate Cyclase, Humans, Hypertension, Pulmonary, Lisuride, Nitric Oxide, Piperazines, Epoprostenol, Pyrazines, Pyrazoles, Pyrimidines, Serotonin Antagonists, Sulfonamides, Drugs, Investigational, Endothelin-1, Protein Kinase Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin A Receptor Antagonists, Endothelin B Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pathways in pulmonary arterial hypertension: the future is here

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks